Morgan Stanley Believes Upside for DENTSPLY International Requires Macro Acceleration or FX Reversal

In a report published Wednesday, Morgan Stanley analyst Steve Beuchaw reiterated an Equal-Weight rating on DENTSPLY International (NASDAQ: XRAY).

In the report, Morgan Stanley noted, “Dentsply is the largest and best managed diversified supplier of dental and orthodontic products, but subject to pressures from the economy and dentists practice cost control efforts. In the event of a macro recovery and persistent execution on targeted M&A, Dentsply is well positioned to drive leverage.”

DENTSPLY International closed on Tuesday at $45.69.